Maze Therapeutics, Inc.
MAZE
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.5B
$26.21
▲ +1.31%
P/E
-9.57
Mkt Cap
$1.5B
52-Wk Range
$14.75–$53.65
52-Week Range
$14.75 - $53.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 75.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Genetics-driven target discovery platform identifying novel disease mechanisms
- Focus on precision medicine addressing underserved patient populations
- First-mover advantage in APOL1-targeted therapeutics with significant market opportunity
- Experienced management team with deep biopharmaceutical and genomics expertise
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Stable outlook
Advancement of MZE829 through Phase II trials with potential for accelerated approval pathways
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+11.2% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MAZE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$0.76 vs -$0.76 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
—
—
-100%
-100%
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.5M
$0
$0
$0
$0
$0
$20.0M
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Truist · $64.00 · Apr 14, 2026
vs Industry
How MAZE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related